Astellas Pharma (ALPMY)
(Delayed Data from OTC)
$12.17 USD
+0.08 (0.66%)
Updated Sep 23, 2024 03:59 PM ET
2-Buy of 5 2
B Value C Growth B Momentum A VGM
Astellas Pharma Inc. (ALPMY) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$12.40 | $12.40 | $12.40 | 2.56% |
Price Target
Only one analyst offered a short-term price target of $12.40 for Astellas Pharma Inc. This represents an increase of 2.56% from the last closing price of $12.09.
Analyst Price Targets (1 )
Broker Rating
Astellas Pharma Inc. currently has an average brokerage recommendation (ABR) of 2.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by four brokerage firms. The current ABR compares to an ABR of 2.50 a month ago based on four recommendations.
Of the four recommendations deriving the current ABR, one is Strong Buy, representing 25% of all recommendations. A month ago, Strong Buy represented 25%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 3 | 3 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.50 | 2.50 | 2.50 | 2.50 | 2.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/18/2024 | Not Identified | Not Identified | Strong Buy | Hold |
2/26/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.50 |
ABR (Last week) | 2.50 |
# of Recs in ABR | 4 |
Average Target Price | $12.40 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 84 of 253 |
Current Quarter EPS Est: | NA |
ALPMY FAQs
Astellas Pharma Inc. (ALPMY) currently has an average brokerage recommendation (ABR) of 2.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 4 brokerage firms.
The average price target for Astellas Pharma Inc. (ALPMY) is $12.40. The current on short-term price targets is based on 3 reports.
The forecasts for Astellas Pharma Inc. (ALPMY) range from a low of $12.4 to a high of $12.4. The average price target represents a increase of $2.56 from the last closing price of $12.09.
The current UPSIDE for Astellas Pharma Inc. (ALPMY) is 2.56%
Only one analyst offered a short-term price target of $12.40 for Astellas Pharma Inc. This represents an increase of 2.56% from the last closing price of $12.09.